BXT 2318 (trastuzumab biosimilar) / BioXpress Therap - LARVOL DELTA

Phase II Study of Paclitaxel Given Once per Week Along With Trastuzumab and Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. (PubMed) - "Treatment was well-tolerated; there was no febrile neutropenia or symptomatic left ventricular systolic dysfunction. Paclitaxel given once per week with trastuzumab and pertuzumab is highly active and well tolerated and seems to be an effective alternative to docetaxel-based combination therapy."

Journal • Biosimilar • Breast Cancer • Oncology • Triple Negative Breast Cancer

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. (PubMed) - Lancet Oncol - "The combination of trastuzumab and lapatinib is active and well tolerated in treatment-refractory patients with HER2-positive metastatic colorectal cancer."

Journal • Biosimilar • Colorectal Cancer • Gastrointestinal Cancer • Graft versus Host Disease • Oncology

Safety And Insurance Premium Implications For Hospitals Based On Subcutaneous Versus Intravenous Administration Of Oncology / Hematology Therapies: Case Studies With Rituximab (Mabthera) And Trastuzumab (Herceptin). (PubMed) - Value Health - No abstract available.

Journal • Biosimilar

Medical resource utilization for administration of trastuzumab in a New Zealand oncology outpatient setting: a time and motion study. (PubMed) - "Compared with trastuzumab IV infusion, administration of trastuzumab via SC injection reduced time spent in the clinic and decreased HCP resources and consumables needed to administer treatment. These reductions could contribute to a decrease in health care costs and an improvement in the efficiency of HER2-positive breast cancer treatment delivery."

Journal • Biosimilar • Breast Cancer • Oncology • Triple Negative Breast Cancer

Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous "manual syringe" injection or intravenously in women with HER2-positive early breast cancer. (PubMed) - Cancer Chemother Pharmacol - "A fixed 600 mg SC dose of trastuzumab provides the desired exposure, with steady-state trough concentrations (35-123 μg/mL for the 5th-95th percentiles) above the historical target concentration of 20 μg/mL for efficacy. Fixed dosing is further supported by lack of an exposure-response relationship between PK, pCR, and grade ≥3 AEs. No dose adjustment per patient factors is required within the ranges studied."

Journal • Biosimilar • Breast Cancer • Oncology • Triple Negative Breast Cancer